During the last three months, 5 analysts shared their evaluations of Capricor Therapeutics (NASDAQ:CAPR), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 1 | 0 | 0 | 0 |
| Last 30D | 2 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $30.6, a high estimate of $40.00, and a low estimate of $8.00. Observing a 27.5% increase, the current average has risen from the previous average price target of $24.00.
Exploring Analyst Ratings: An In-Depth Overview
A clear picture of Capricor Therapeutics’s perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Aydin Huseynov | Ladenburg Thalmann | Raises | Buy | $25.00 | $24.00 |
| Kristen Kluska | Cantor Fitzgerald | Maintains | Overweight | $8.00 | – |
| Joseph Pantginis | HC Wainwright & Co. | Maintains | Buy | $40.00 | – |
| Joseph Pantginis | HC Wainwright & Co. | Maintains | Buy | $40.00 | – |
| Joseph Pantginis | HC Wainwright & Co. | Maintains | Buy | $40.00 | – |
Key Insights:
Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they ‘Maintain’, ‘Raise’ or ‘Lower’ their stance, it reflects their reaction to recent developments related to Capricor Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.
Rating: Gaining insights, analysts provide qualitative assessments, ranging from ‘Outperform’ to ‘Underperform’. These ratings reflect expectations for the relative performance of Capricor Therapeutics compared to the broader market.
Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Capricor Therapeutics’s future value. Comparing current and prior targets offers insights into analysts’ evolving expectations.
Analyzing these analyst evaluations alongside…
Click Here to Read the Full Original Article at Cryptocurrencies Feed…
